公开(公告)号：US20240352123A1

公开(公告)日：2024-10-24

申请号：US18715007

申请日：2022-12-02

申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION ,  UNIVERSITY OF MARYLAND BALTIMORE, OFFICE OF TECHNOLOGY TRANSFER

发明人： Tim C. Luetkens ,  Erica Vander Mause ,  Djordje Atanackovic

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K45/06 ,  A61P35/00 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70521 ,  C07K14/70578 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/42

摘要： Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 binding domain is a variant CD229 antigen binding domain. Disclosed are chimeric antigen receptor (CAR) polypeptides comprising a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the CD229 antigen binding domain comprises the sequence of SEQ ID NO:134, SEQ ID NO:53, or SEQ ID NO:84. Disclosed are methods of using the CAR polypeptides or antibodies comprising the same CD229 antigen binding domain as the CAR polypeptides.

公开(公告)号：US20240197877A1

公开(公告)日：2024-06-20

申请号：US18286726

申请日：2022-04-14

申请人： TScan Therapeutics, Inc.

发明人： Ribhu Nayar ,  Gavin MacBeath ,  Sonal Jangalwe ,  Mollie M. Jurewicz ,  Andrew S. Basinski ,  Qikai Xu ,  Antoine J. Boudot ,  Tomasz Kula

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/10 ,  C12N5/0783 ,  G01N33/574 ,  G01N33/68

CPC分类号： A61K39/4632 ,  A61K39/4611 ,  A61K39/464838 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/1018 ,  C12N5/0636 ,  G01N33/57484 ,  G01N33/6893 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2319/40 ,  C07K2319/41 ,  C07K2319/42 ,  C07K2319/43 ,  C12N2510/00

摘要： Provided herein are binding proteins recognizing HA-2 antigen and uses thereof.

公开(公告)号：US20230272040A1

公开(公告)日：2023-08-31

申请号：US18019179

申请日：2021-08-19

申请人： SHANDONG BOAN BIOTECHNOLOGY CO., LTD.

发明人： Li ZHOU ,  Michael HARRIS

IPC分类号： C07K14/725 ,  C12N5/0783 ,  C07K14/715 ,  C07K14/705 ,  C07K14/005 ,  C07K14/435 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K14/7051 ,  C12N5/0636 ,  C07K14/7155 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70521 ,  C07K14/005 ,  C07K14/43504 ,  A61P35/00 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464406 ,  A61K39/464411 ,  A61K39/464419 ,  A61K39/464838 ,  A61K39/464402 ,  A61K39/4642 ,  C07K2319/03 ,  C07K2317/622 ,  C07K2317/53 ,  C07K2319/42

摘要： The present application relates to a chimeric antigen receptor (CAR) which comprises a target-dependent on-switch CAR. The CAR of the invention may reduce cytotoxicity towards normal cells and improve CAR-T safety. CAR molecules were designed using the transmembrane and juxtamembrane motifs of the IL2 receptor β chain (IL2Rβ or IL2Rb), the L ow-Density Lipoprotein Receptor (LDLR), the Seizure 6-like Protein 2 (SEZ6L2), and degradation sequence (PSKFFSQL) of IL2Rβ, which resulted in greatly reduced CAR expression at the cell surface in the absence of target antigen, while retaining downstream activation ability in response to antigen-expressing target cells. In the absence of target antigen, CAR surface expression is undetectable. The present application has shown that primary T cells expressing these surface-unstable CAR variants are able to elicit antigen-dependent target cell killing. By limiting CAR activity in this way, the present application can reduce therapeutic toxicity and T cell exhaustion. Due to its limited detectability in the absence of antigen, the present application refers to this system as a “Stealth CAR”. The present application further relates to compositions, preparation methods and uses of the Stealth CAR of the present application.

公开(公告)号：US20230250135A1

公开(公告)日：2023-08-10

申请号：US17753506

申请日：2020-09-03

申请人： JANSSEN VACCINES & PREVENTION B.V.

发明人： Mandy Antonia Catharina JONGENEELEN ,  Tina RITSCHEL ,  Ferdinand Jacobus MILDER ,  Indigo KING ,  Yifan SONG ,  Johannes Petrus Maria LANGEDIJK ,  Boerries BRANDENBURG

IPC分类号： C07K14/005 ,  A61P31/16

CPC分类号： C07K14/005 ,  A61P31/16 ,  C07K2319/42 ,  A61K39/00

摘要： Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.

公开(公告)号：US20190192650A1

公开(公告)日：2019-06-27

申请号：US16298006

申请日：2019-03-11

申请人： The Trustees of the University of Pennsylvania ,  Inovio Pharmaceuticals, Inc.

发明人： David Weiner ,  Jian Yan

IPC分类号： A61K39/12 ,  A61N1/32 ,  C07K14/005

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/70 ,  A61N1/327 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/42 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16041 ,  C12N2760/16071 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2800/22

摘要： Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV39 E6E7 and HPV45 E6E7. Pharmaceutical composition, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed.

公开(公告)号：US20180312546A1

公开(公告)日：2018-11-01

申请号：US15981316

申请日：2018-05-16

申请人： Drexel University ,  Baruch S. Blumberg Institute ,  Hoffmann-La Roche Inc.

发明人： Haitao Guo ,  Dawei Cai ,  Andrea Cuconati ,  Changhua Ji

IPC分类号： C07K14/005 ,  G01N33/50

CPC分类号： C07K14/005 ,  C07K2319/40 ,  C07K2319/42 ,  C12N2730/10122 ,  C12N2730/10151 ,  C12N2830/006 ,  G01N33/502 ,  G01N2333/02

摘要： The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

公开(公告)号：US10072047B2

公开(公告)日：2018-09-11

申请号：US15309680

申请日：2015-06-19

申请人： Drexel University ,  Baruch S. Blumberg Institute ,  Hoffmann-La Roche Inc.

发明人： Haitao Guo ,  Dawei Cai ,  Andrea Cuconati ,  Changhua Ji

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/715 ,  A01N37/18 ,  A61K31/16 ,  C07K14/005 ,  G01N33/50

CPC分类号： C07K14/005 ,  C07K2319/40 ,  C07K2319/42 ,  C12N2730/10122 ,  C12N2730/10151 ,  C12N2830/006 ,  G01N33/502 ,  G01N2333/02

摘要： The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

公开(公告)号：US20180208943A1

公开(公告)日：2018-07-26

申请号：US15836345

申请日：2017-12-08

申请人： Daniel Schmidt

发明人： Daniel Schmidt

IPC分类号： C12N15/86 ,  C07K14/00 ,  C07K14/435 ,  C07K14/46 ,  C12N15/10 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/0008 ,  C07K14/00 ,  C07K14/005 ,  C07K14/43518 ,  C07K14/46 ,  C07K2319/02 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/42 ,  C07K2319/55 ,  C07K2319/60 ,  C07K2319/70 ,  C12N15/1082 ,  C12N15/1093 ,  C12N2750/14122 ,  C12N2750/14145 ,  C12N2750/14151 ,  C12N2750/14171

摘要： Methods to prepare recombinant adeno-associated virus (AAV) capsids with altered tropism and compositions having AAVs with altered tropism are provided.

公开(公告)号：US10004799B2

公开(公告)日：2018-06-26

申请号：US15447972

申请日：2017-03-02

申请人： Longhorn Vaccines and Diagnostics, LLC

发明人： Gerald W. Fischer ,  Luke T. Daum

IPC分类号： A61K39/145 ,  C07K14/33 ,  A61K39/12 ,  A61K39/04 ,  C07K14/35 ,  C07K16/10 ,  C07K16/12 ,  C12N7/00 ,  A61K39/00 ,  C07K14/005

CPC分类号： A61K39/145 ,  A61K39/04 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6043 ,  A61K2039/6068 ,  A61K2039/70 ,  C07K14/005 ,  C07K14/33 ,  C07K14/35 ,  C07K16/1018 ,  C07K16/1289 ,  C07K2319/40 ,  C07K2319/42 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16161

摘要： The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.

公开(公告)号：US09777045B2

公开(公告)日：2017-10-03

申请号：US15205476

申请日：2016-07-08

申请人： Longhorn Vaccines and Diagnostics, LLC

发明人： Gerald W. Fischer ,  Luke T. Daum

IPC分类号： C07K14/005 ,  C07K14/33 ,  C07K14/35 ,  C07K7/06 ,  C12N7/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/102 ,  A61K39/09 ,  A61K39/00 ,  A61K39/085

CPC分类号： C07K14/005 ,  A61K39/085 ,  A61K39/092 ,  A61K39/102 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/6043 ,  A61K2039/6068 ,  A61K2039/70 ,  C07K7/06 ,  C07K14/33 ,  C07K14/35 ,  C07K2319/40 ,  C07K2319/42 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16161

摘要： Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.